Pharmaceutical

Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K

CHICAGO, IL / ACCESSWIRE / April 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 months ago

Sunshine Biopharma’s Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching…

2 months ago

Nutriband Inc. Announces $8.4M Private Placement

Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL…

2 months ago

CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

2 months ago

Preliminary Results for the Year Ended 31 December 2023

19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the…

2 months ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)…

2 months ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market…

2 months ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market…

2 months ago

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented…

2 months ago

Addex to Present at the Swiss Biotech Day 2024

Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug…

2 months ago